News - Tecfidera, Women's Health

Filter

Current filters:

TecfideraWomen's Health

Popular Filters

1 to 25 of 104 results

Mylan settles over generic Generess tablets and launches insomnia drug

Mylan settles over generic Generess tablets and launches insomnia drug

16-04-2014

US generics major Mylan (Nasdaq: MYL) and its partner Famy Care have entered into a settlement and license…

ActavisFamy CareGeneress FeGenericsHealth Medical PharmaLegalLunestaMylanMylan LaboratoriesPharmaceutical sciencesPharmacologyUSAWomen's Health

Merck, Ferring and WHO working together to prevent excessive bleeding in women after childbirth

Merck, Ferring and WHO working together to prevent excessive bleeding in women after childbirth

06-04-2014

US pharma giant Merck & Co and privately-held Switzerland-headquartered Ferring Pharmaceuticals have…

carbetocinFerring PharmaceuticalsGlobalMarkets & MarketingMerck & CoPharmaceuticalResearchWomen's Health

GSK withdraws European marketing authorization for ovarian cancer drug Votrient

GSK withdraws European marketing authorization for ovarian cancer drug Votrient

31-03-2014

UK pharma major GlaxoSmithKline has withdrawn its application to the European Medicines Agency for a…

GlaxoSmithKlineOncologyPharmaceuticalRegulationUKVotrientWomen's Health

US FDA approves NDA from Actavis and Valeant

US FDA approves NDA from Actavis and Valeant

26-03-2014

US generics major Actavis and Canada’s Valeant Pharmaceuticals said that the US Food and Drug Administration…

ActavisCanadaGenericsMetronidazolePharmaceuticalRegulationUSAValeant PharmaceuticalsWomen's Health

Mike Sullivan appointed president of Avion Pharmaceuticals

Mike Sullivan appointed president of Avion Pharmaceuticals

18-03-2014

Avion Pharmaceuticals, a US-based specialty pharmaceutical company, has announced the promotion of Mike…

Avion PharmaceuticalsBoardroomNovartisPharmaceuticalReproductiveSanofiTher-RxUSAWomen's Health

Dilafor partners with Lee’s Pharmaceutical for tafoxiparin

24-02-2014

Sweden-based Dilafor AB, a Karolinska Development portfolio company, and Lee’s Pharmaceutical Holdings,…

Asia-PacificChinaDilafor ABKarolinska DevelopmentLee's PharmaceuticalLicensingPharmaceuticalReproductivetafoxiparinWomen's Health

NICE asks Biogen Idec for more information on Tecfidera

NICE asks Biogen Idec for more information on Tecfidera

21-02-2014

The UK’s National Institute for Health and Care Excellence (NICE) is calling on US biotech firm Biogen…

Biogen IdecBiotechnologyCNS DiseasesRegulationTecfideraUK

Sprout Pharmaceuticals to resubmit NDA for flibanserin

Sprout Pharmaceuticals to resubmit NDA for flibanserin

12-02-2014

US privately-held sexual health specialists Sprout Pharmaceuticals has received ‘clear guidance’…

flibanserinPharmaceuticalRegulationSprout PharmaceuticalsUSAWomen's Health

Biogen’s MS drug Tecfidera approved in EU

Biogen’s MS drug Tecfidera approved in EU

03-02-2014

US biotech firm Biogen Idec’s Tecfidera (dimethyl fumarate) has been approved by the European Commission…

Biogen IdecBiotechnologyEuropeNeurologicalRegulationTecfidera

UCB and Biogen sign Asian license agreement for MS drugs

UCB and Biogen sign Asian license agreement for MS drugs

30-01-2014

Belgian drugmaker UCB and US biotech firm Biogen Idec have signed exclusive agreements granting UCB the…

AlprolixAsia-PacificBiogen IdecBiotechnologyEloctateLicensingNeurologicalPharmaceuticalTecfideraUCB

Biogen Idec beats on sales and earnings, with shinning performance from Tecfidera

Biogen Idec beats on sales and earnings, with shinning performance from Tecfidera

29-01-2014

US biotech firm Biogen Idec reported full year and fourth quarter 2013 results that beat consensus Wall…

Biogen IdecBiotechnologyFinancialTecfidera

European Commission approves Gedeon Richter’s Esmya type II Variation

European Commission approves Gedeon Richter’s Esmya type II Variation

27-01-2014

The European Commission has granted marketing authorization to extend the use of Esmya (ulipristal acetate)…

EsmyaEuropeGedeon RichterPharmaceuticalRegulationWomen's Health

Advaxis out-licenses ADXS-HPV to Biocon for emerging markets

Advaxis out-licenses ADXS-HPV to Biocon for emerging markets

23-01-2014

Indian biotech firm Biocon has entered into an exclusive licensing agreement for US cancer drug developer…

AdvaxisADXS-HPVAsia-PacificBioconIndiaLicensingOncologyPharmaceuticalWomen's Health

EMA pharmacovigilance unit calls for suspension of Protelos/Osseor

EMA pharmacovigilance unit calls for suspension of Protelos/Osseor

10-01-2014

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has recommended…

Anti-Arthritics/RheumaticsEuropeOsseorPharmaceuticalProtelosRegulationServierWomen's Health

Royalty Pharma acquires additional interest in Tecfidera for $510 million

Royalty Pharma acquires additional interest in Tecfidera for $510 million

06-01-2014

US private equity firm Royalty Pharma says that it has acquired an additional interest in the earn-out…

Biogen IdecDermatologicalsFumadermFumapharmLicensingNeurologicalPharmaceuticalRoyalty PharmaTecfidera

Two Latin America acquisitions for Gedeon Richter

23-12-2013

In what was a busy couple of days for Hungary’s largest drugmaker Gedeon Richter, the company announced…

BrazilGedeon RichterMergers & AcquisitionsNext PharmaPharmaceuticalSouth AmericaWomen's Health

Torrent to acquire Indian branded formulations from Elder

13-12-2013

Torrent Pharmaceuticals saw its shares rise 7% to 349 rupees after it said it is acquiring the branded…

Asia-PacificElder PharmaceuticalsIndiaMergers & AcquisitionsNeurologicalPharmaceuticalTorrent PharmaceuticalsWomen's Health

Retrophin to acquire Kyalin Biosciences; in-licenses Syntocinon

13-12-2013

In a second takeover bid within a matter of months, USA-based Retrophin announced that it will acquire…

Kyalin BiosciencesLicensingMergers & AcquisitionsNeurologicalNorth AmericaNovartisPharmaceuticalRetrophinSyntocinonWomen's Health

No increase in risk of autism from taking SSRIs in pregnancy

25-11-2013

New research cannot establish a close connection between the use of antidepressant medication - the so-called…

NeurologicalPharmaceuticalResearchWomen's Health

Biogen prevails in EU exclusivity battle for MS drug Tecfidera

Biogen prevails in EU exclusivity battle for MS drug Tecfidera

25-11-2013

US biotech company Biogen Idec saw its shares leap 10% to an all-time high of nearly $278 on Friday,…

Biogen IdecBiotechnologyEuropeNeurologicalPatentsRegulationTecfidera

Benefits of combined hormonal contraceptives continue to outweigh risks, says EMA/CHMP

Benefits of combined hormonal contraceptives continue to outweigh risks, says EMA/CHMP

23-11-2013

The European Medicines Agency has now completed its review of combined hormonal contraceptives (CHCs),…

EuropePharmaceuticalRegulationReproductiveWomen's Health

Merck’s new HPV vaccine could rejuvenate market, says GlobalData

Merck’s new HPV vaccine could rejuvenate market, says GlobalData

18-11-2013

Despite being hampered both by apathy and resistance in recent years, the human papillomavirus (HPV)…

CervarixGardasilGlaxoSmithKlineMarkets & MarketingMerck & CoPharmaceuticalV503VaccinesWomen's Health

2013 FDA approval rates suggest record year for post-launch success

14-11-2013

A focus on hard to treat or specialist diseases is set to result in record post-launch sales for new…

Biogen IdecFinancialGilead SciencesNorth AmericaPharmaceuticalRegulationsofosbuvirTecfidera

1 to 25 of 104 results

Back to top